...
首页> 外文期刊>Cellular Physiology and Biochemistry >SIRT1 Regulates CD40 Expression Induced by TNF-_α via NF-_κB Pathway in Endothelial Cells
【24h】

SIRT1 Regulates CD40 Expression Induced by TNF-_α via NF-_κB Pathway in Endothelial Cells

机译:SIRT1调节TNF-α通过NF-κB途径在内皮细胞中诱导的CD40表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Compelling evidence suggests that SIRT1, NAD+-dependent class III protein deacetylase, plays an important role in the prevention and treatment of atherosclerosis by counteracting inflammation. Cluster of differentiation 40 (CD40), as a pro-inflammatory cytokine, has been shown to participate in the pathophysiology of atherosclerosis. The relationship between SIRT1 and CD40, however, remained elusive. The present study was thus designed to explore the potential effect of SIRT1 on CD40 expression induced by tumor necrosis factor-α (TNF-α) and to disclose the underlying mechanism in CRL-1730 endothelial cells. Methods: mRNA and protein expressions were identified by quantitative real-time PCR and Western blot respectively. Subcellular localization of SIRT1 was detected by immunofluorescence analysis. SIRT1 small-interfering RNA (siRNA) was carried out for mechanism study. Results: TNF-α reduced SIRT1 expression and induced CD40 expression in CRL-1730 endothelial cells in a time- and concentration- dependent manner. Pretreatment with resveratrol (a potent SIRT1 activator) inhibited TNF-α-induced CD40 expression, while pretreatment with nicotinamide (class b HDACs inhibitor nicotinamide) or sirtinol (a known SIRT1 inhibitor), especially SIRT1 siRNA significantly augmented TNF-α-induced CD40 expression. The frther sudy idicated that PDTC (NF-κB inhibitor) pretreatment attenuated TNF-α-induced CD40 expression, and SIRT1 siRNA significantly augmented TNF-α-induced acetylated-NF-κB p65 (Lys310) expression. Conclusion: The present study provides the direct evidence that SIRT1 can inhibit TNF-α-induced CD40 expression in CRL-1730 endothelial cells by deacetylating the RelA/p65 subunit of NF-κB at lysine 310, which provides new insights into understanding of the anti-inflammatory and anti-athroscerotic actions of SIRT1.
机译:背景:有力的证据表明,SIRT1是NAD +依赖性的III类蛋白质脱乙酰基酶,可通过抵消炎症在预防和治疗动脉粥样硬化中起重要作用。分化簇40(CD40),作为促炎细胞因子,已被证明参与动脉粥样硬化的病理生理。但是,SIRT1和CD40之间的关系仍然难以捉摸。因此,本研究旨在探讨SIRT1对肿瘤坏死因子-α(TNF-α)诱导的CD40表达的潜在作用,并揭示CRL-1730内皮细胞的潜在机制。方法:采用实时荧光定量PCR和蛋白质印迹法分别检测mRNA和蛋白表达。通过免疫荧光分析检测SIRT1的亚细胞定位。进行了SIRT1小干扰RNA(siRNA)的机理研究。结果:TNF-α以时间和浓度依赖性方式降低了CRL-1730内皮细胞中SIRT1的表达并诱导CD40的表达。用白藜芦醇(一种有效的SIRT1激活剂)预处理抑制了TNF-α诱导的CD40表达,而用烟酰胺(b类HDAC抑制剂烟酰胺)或sirtinol(一种已知的SIRT1抑制剂)尤其是SIRT1 siRNA的预处理显着增强了TNF-α诱导的CD40表达。 。进一步的研究表明PDTC(NF-κB抑制剂)预处理减弱了TNF-α诱导的CD40表达,而SIRT1 siRNA显着增强了TNF-α诱导的乙酰化NF-κBp65(Lys310)表达。结论:本研究提供直接证据,表明SIRT1可以通过在赖氨酸310处使NF-κB的RelA / p65亚基脱乙酰化而抑制CRL-1730内皮细胞中TNF-α诱导的CD40表达,这为了解抗RT-1基因提供了新的见解。 -SIRT1的抗炎和抗动脉粥样硬化作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号